These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1428727)
1. Phase I study of mitonafide in solid tumors. Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of mitonafide in non-small cell lung cancer (NSCLC). Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characterization of mitonafide in man. Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study. Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K; Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of amonafide in advanced breast cancer. Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of amonafide in advanced and recurrent sarcoma patients. Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272 [TBL] [Abstract][Full Text] [Related]
12. Phase I clinical investigation of benzisoquinolinedione. Legha SS; Ring S; Raber M; Felder TB; Newman RA; Krakoff IH Cancer Treat Rep; 1987 Dec; 71(12):1165-9. PubMed ID: 3690526 [TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study. Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018 [TBL] [Abstract][Full Text] [Related]
15. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR; Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of high-dose etoposide phosphate in man. Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836 [TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916 [TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Mullane MR; Schilsky RL; Carroll RB; Wade JL; Kilton LJ; Blough RR; Bauman A; French SL; Benson AB Invest New Drugs; 1994; 12(3):267-70. PubMed ID: 7896548 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Linke K; Pazdur R; Abbruzzese JL; Ajani JA; Winn R; Bradof JE; Daugherty K; Levin B Invest New Drugs; 1991 Nov; 9(4):353-6. PubMed ID: 1804812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]